Sana Biotechnology, Inc.
SANA
$3.27
-$0.09-2.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.47% | -26.81% | -37.11% | -29.41% | -16.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.46% | -26.04% | -16.45% | -53.71% | -32.78% |
| Operating Income | -1.46% | 26.04% | 16.45% | 53.71% | 32.78% |
| Income Before Tax | -19.88% | 29.66% | -86.51% | 54.05% | 44.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.88% | 29.66% | -86.51% | 54.05% | 44.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.88% | 29.66% | -86.51% | 54.05% | 44.31% |
| EBIT | -1.46% | 26.04% | 16.45% | 53.71% | 32.78% |
| EBITDA | -3.14% | 26.37% | 15.64% | 55.59% | 34.08% |
| EPS Basic | -2.65% | 36.42% | -83.40% | 57.97% | 53.49% |
| Normalized Basic EPS | 9.88% | 33.19% | 21.45% | 57.43% | 49.05% |
| EPS Diluted | -2.65% | 36.42% | -83.40% | 57.97% | 53.49% |
| Normalized Diluted EPS | 9.88% | 33.19% | 21.45% | 57.43% | 49.05% |
| Average Basic Shares Outstanding | 16.75% | 10.65% | 1.69% | 9.34% | 19.76% |
| Average Diluted Shares Outstanding | 16.75% | 10.65% | 1.69% | 9.34% | 19.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |